These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31040907)

  • 1. The BET-bromodomain inhibitor JQ1 renders neuroblastoma cells more resistant to NK cell-mediated recognition and killing by downregulating ligands for NKG2D and DNAM-1 receptors.
    Veneziani I; Fruci D; Compagnone M; Pistoia V; Rossi P; Cifaldi L
    Oncotarget; 2019 Mar; 10(22):2151-2160. PubMed ID: 31040907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.
    Brandetti E; Veneziani I; Melaiu O; Pezzolo A; Castellano A; Boldrini R; Ferretti E; Fruci D; Moretta L; Pistoia V; Locatelli F; Cifaldi L
    Oncoimmunology; 2017; 6(6):e1316439. PubMed ID: 28680748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.
    Veneziani I; Brandetti E; Ognibene M; Pezzolo A; Pistoia V; Cifaldi L
    J Immunol Res; 2018; 2018():4972410. PubMed ID: 29805983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of Neuroblastoma NK-Cell-Mediated Lysis through NF-kB p65 Subunit-Induced Expression of FAS and PVR, the Loss of Which Is Associated with Poor Patient Outcome.
    Brandetti E; Focaccetti C; Pezzolo A; Ognibene M; Folgiero V; Cotugno N; Benvenuto M; Palma P; Manzari V; Rossi P; Fruci D; Bei R; Cifaldi L
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Killing of Human Neuroblastoma Cells by the Small Molecule JQ1 Occurs in a p53-Dependent Manner.
    Mazar J; Gordon C; Naga V; Westmoreland TJ
    Anticancer Agents Med Chem; 2020; 20(13):1613-1625. PubMed ID: 32329693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
    Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
    Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
    Kim JY; Bae JH; Lee SH; Lee EY; Chung BS; Kim SH; Kang CD
    J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells
    Focaccetti C; Benvenuto M; Pighi C; Vitelli A; Napolitano F; Cotugno N; Fruci D; Palma P; Rossi P; Bei R; Cifaldi L
    Front Immunol; 2022; 13():886319. PubMed ID: 35967339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK cell recognition and killing of melanoma cells is controlled by multiple activating receptor-ligand interactions.
    Morgado S; Sanchez-Correa B; Casado JG; Duran E; Gayoso I; Labella F; Solana R; Tarazona R
    J Innate Immun; 2011; 3(4):365-73. PubMed ID: 21576932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutically targeting oncogenic CRCs facilitates induced differentiation of NB by RA and the BET bromodomain inhibitor.
    Alleboina S; Aljouda N; Miller M; Freeman KW
    Mol Ther Oncolytics; 2021 Dec; 23():181-191. PubMed ID: 34729395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.
    Textor S; Fiegler N; Arnold A; Porgador A; Hofmann TG; Cerwenka A
    Cancer Res; 2011 Sep; 71(18):5998-6009. PubMed ID: 21764762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The BET Protein Inhibitor JQ1 Decreases Hypoxia and Improves the Therapeutic Benefit of Anti-PD-1 in a High-Risk Neuroblastoma Mouse Model.
    Sauvage D; Bosseler M; Viry E; Kanli G; Oudin A; Berchem G; Keunen O; Janji B
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses.
    Zingoni A; Ardolino M; Santoni A; Cerboni C
    Front Immunol; 2012; 3():408. PubMed ID: 23316196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent targeting of MAP3K3 and BRD4 by
    Liu C; Gen Y; Tanimoto K; Muramatsu T; Inoue J; Inazawa J
    Mol Ther Nucleic Acids; 2021 Sep; 25():83-92. PubMed ID: 34258104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
    El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
    Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells.
    Cappel C; Huenecke S; Suemmerer A; Erben S; Rettinger E; Pfirrmann V; Heinze A; Zimmermann O; Klingebiel T; Ullrich E; Bader P; Bremm M
    Pediatr Blood Cancer; 2016 Dec; 63(12):2230-2239. PubMed ID: 27433920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of
    Li Z; Lim SL; Tao Y; Li X; Xie Y; Yang C; Zhang Z; Jiang Y; Zhang X; Cao X; Wang H; Qian G; Wu Y; Li M; Fang F; Liu Y; Fu M; Ding X; Zhu Z; Lv H; Lu J; Xiao S; Hu S; Pan J
    Front Oncol; 2020; 10():574525. PubMed ID: 33324552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
    Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
    Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.